Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.
about
In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transferGene therapy for severe combined immunodeficiency: are we there yet?In situ transduction of stromal cells and thymocytes upon intrathymic injection of lentiviral vectorsEstablishment and Maintenance of the Human Naïve CD4+ T-Cell CompartmentTherapeutic genome editing: prospects and challengesSevere combined immunodeficiencies (SCID)Gene therapy for PIDs: progress, pitfalls and prospectsThe dynamics of T-cell receptor repertoire diversity following thymus transplantation for DiGeorge anomalyTranscription activator-like effector nuclease-mediated transduction of exogenous gene into IL2RG locusHypomorphic Rag mutations can cause destructive midline granulomatous disease.Gene therapy for inherited immunodeficiency.Homeostatic properties and phenotypic maturation of murine CD4+ pre-thymic emigrants in the thymus.Primary immunodeficiency diseases: natural mutant models for the study of the immune system.In vivo reversion to normal of inherited mutations in humans.Clinical applications of gene therapy for primary immunodeficiencies.Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.The many important facets of T-cell repertoire diversity.Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach.Severe combined immunodeficiency. A model disease for molecular immunology and therapy.Survival of the fittest: in vivo selection and stem cell gene therapyGene therapy for treatment of inherited haematological disorders.Update on clinical gene therapy in childhood.Somatic mosaicism in Wiskott--Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism.Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.Homologous recombination-based gene therapy for the primary immunodeficiencies.Current progress on gene therapy for primary immunodeficiencies.Lentiviral vectors for the treatment of primary immunodeficiencies.Gene therapy for primary immunodeficiencies: current status and future prospects.Genome Editing of the Blood: Opportunities and ChallengesA reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cellsT cell-specific expression from Mo-MLV retroviral vectors containing a CD4 mini-promoter/enhancer.The developing human immune system: T-cell receptor repertoire of children and young adults shows a wide discrepancy in the frequency of persistent oligoclonal T-cell expansions.A tale of two SCIDs.Severe combined immunodeficiencies and related disorders.Selective growth advantage of wild-type lymphocytes in X-linked SCID recipients.Gene therapy of severe combined immunodeficienciesT cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency
P2860
Q24532255-78D043F9-6AEC-4CC5-87BE-084BCF52CE73Q24680426-1E92B92C-DF33-4B5E-A7F7-D91674459288Q24805129-6458699F-2BCB-4EB3-B9AA-2DC202E49E7CQ28080000-707BF7B0-D9BD-41A4-9702-F37701B501D4Q28087380-6CEBF795-8D67-4600-8F04-2F518187D3D4Q29042256-FEB8D3DF-EB3A-4430-9658-D5405DF2F101Q33406944-7E74146C-8E91-48FB-9968-EA83219C332EQ33466761-F3F3735A-0F2B-4F04-A896-7B55456EE923Q33651871-B730F777-3C48-4898-9503-70FA89FC96FAQ34122665-3E6B6757-3087-41E6-9E71-E1540A7FDDA2Q34419791-785CAEBB-C341-460E-AFFE-761EBBB7CDA5Q34586912-4DA340CB-9705-4117-912A-E82D271EDD48Q34592462-830463D4-E062-4D07-A978-DCAFDEB5D7A8Q35440872-1B31CFA6-CCF5-4BCF-9F02-9275FB362809Q35539617-E1266E5E-AB36-48CC-BA3F-C700CFC2FCB7Q35701287-FBCD2EB9-7354-4307-B210-B8E6FC1F3D0BQ35709655-3BFB636E-92CF-47DF-9CAB-7F227F389EECQ35926877-96FCA1AA-D107-4479-9E84-5A84C70939EFQ36015021-5B0C5E6E-6A1E-4CCF-9934-CAD8D1723C5CQ36306141-B5003596-5570-48BC-8311-DC6D7987B497Q36446948-380A7212-3470-4D50-97FF-4F4E568F5BD9Q36978568-5A748B14-4035-4D39-82EF-34106610150EQ37111771-CE24FF69-ECCF-4E51-B430-CD3CD7BF06BFQ37414711-FED949E9-C1F3-4BD0-8B81-9248821EE185Q37974988-844861F4-FB60-4E71-BC06-EA2A7EF70A73Q38110363-C174CDAD-C627-42F9-94DB-47197DA33D06Q38195200-324BD65A-602E-4CED-8CE9-AB91D271765EQ38213501-A5261D6F-8A9B-4873-81C8-D5D38177F93AQ41087426-7C7738A5-C296-4EB4-9060-7BB3297FDEAFQ41471275-06B1B287-747E-40F1-943A-4BF82C5576DAQ42831809-FC1C0F80-99D1-4346-AD36-74E24EF78F57Q43857531-FEE4ECE6-9248-407D-9180-050DFC07B17BQ45872708-58362450-0E37-40A3-A5A7-3897C2BAECFEQ45886049-BDA11C57-626B-452F-8492-17F620C21236Q45887949-5981CB2A-AA8B-4BE4-9574-107E8CFAC954Q55982397-327D0548-B5EC-43B1-B6D9-FE76B05C87B4Q59126661-A88CFFB2-78B8-464E-BB58-2FF89129A391
P2860
Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diversity, functionality, and ...... single human T cell precursor.
@en
Diversity, functionality, and ...... single human T cell precursor.
@nl
type
label
Diversity, functionality, and ...... single human T cell precursor.
@en
Diversity, functionality, and ...... single human T cell precursor.
@nl
prefLabel
Diversity, functionality, and ...... single human T cell precursor.
@en
Diversity, functionality, and ...... single human T cell precursor.
@nl
P2093
P2860
P356
P1476
Diversity, functionality, and ...... single human T cell precursor
@en
P2093
C Pannetier
F Le Deist
P Kourilsky
P2860
P304
P356
10.1073/PNAS.97.1.274
P407
P577
2000-01-01T00:00:00Z